搜尋結果
Acute coronary syndrome (ACS) is now a major cause of death and disability in this region with in-hospital mortality typically exceeding 5%. Yet, the region still lacks consensus on the best approach to overcoming its specific challenges in reducing mortality from ACS.
- Mark Y. Chan, Xin Du, David Eccleston, Changsheng Ma, Padinhare P. Mohanan, Manabu Ogita, Kou Gi Shy...
- 2016
2024年10月2日 · Coronary heart disease corresponds to codes 410-414 in ICD-9 and I20-I25 in ICD-10. Heart diseases claimed about 74000 inpatient discharges and inpatient deaths in all hospitals †, and 6791 registered deaths ‡ in 2022. They were the fourth commonest cause of deaths in Hong Kong and accounting for 11.0% of all registered deaths in 2022.
Among people aged 50 or above, coronary heart disease even was the top-ranked cause of ill health, disability and death. ※ Studies also show that pre-existing heart disease is a prominent risk factor for severe coronavirus disease 2019 (COVID-19) and death.
- 969KB
- 7
2018年8月15日 · Background: Individuals are at increased risk for cardiovascular events following an acute coronary syndrome (ACS). Effective management of hyperlipidemia, an associated risk factor, is essential for improving outcomes. We aimed to quantify the extent of
- Bryan P. Yan, Fu-Tien Chiang, Baishali Ambegaonkar, Philippe Brudi, Martin Horack, Dominik Lautsch, ...
- 2018
MANAGEMENT OF ACUTE CORONARY SYNDROME. Definition: ACS consists of STEMI, NSTEMI and unstable angina. STEMI and NSTEMI are associated with rise in cardiac biomarker, whereas unstable angina is the presence of ischaemic symptoms without elevation in cardiac biomarker with/ without ECG changes.
2015年10月7日 · Encompassing unstable angina, non–ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI), acute coronary syndrome (ACS) is a more severe type of coronary heart disease (CHD) attributed to the rupture
2015年10月7日 · Abstract. Background: Utilization of lipid-lowering agents has been associated with improved long-term outcomes in acute coronary syndrome (ACS) patients. However, updated data regarding local use and outcomes was lacking.
